Data from Phase 3 TRuE-AD Trials of Ruxolitinib Cream in Atopic Dermatitis to be Presented at the 2020 Revolutionizing Atopic Dermatitis Virtual Conference

Investor conference call and webcast scheduled for Monday, April 6, 2020 at 8:00 a.m. EDT

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that data from the Phase 3 TRuE-AD program evaluating ruxolitinib cream for the treatment of patients with mild-to-moderate atopic dermatitis have been accepted for presentation during the Late Breaking Abstracts session at the 2020 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference to be held on Sunday, April 5, 2020. The TRuE-AD data presentation at RAD will include additional efficacy and safety data beyond those included in the topline press release issued on February 19, 2020.

More information regarding the virtual conference is available on the RAD website.

Conference Call Information

Incyte will host an investor conference call and webcast at 8:00 a.m. EDT on Monday, April 6, 2020. The webcast will be available via investor.incyte.com.

To access the conference call on Monday, April 6, 2020, please dial 877-407-3042 for domestic callers or [phone] for international callers. When prompted, provide the conference identification number, 13700027.

If you are unable to participate, a replay of the conference call will be available for 30 days. The replay dial-in number for the United States is 877-660-6853 and the dial-in number for international callers is [phone]. To access the replay you will need the conference identification number, 13700027.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.